Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
|Articles|October 7, 2021
NIIMBL Invests $3 Million in Six Biopharmaceutical Manufacturing Products
Author(s)BioPharm International Editors
The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.
Advertisement
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced on Oct. 5th, 2021, that they would invest $3 million in six new biopharmaceutical manufacturing products. Each project will measure glycans through liquid chromatography–mass spectrometry (LC-MS) in some way.
The institutions receiving funding include:
- North Carolina State University
- University of Massachusetts
- University of Georgia
- University of Michigan
- University of Delaware
- Carnegie Mellon University
According to a press release from NIIMBL, each of these projects is specifically geared toward supporting NIIMBL’s Project Call 5.1. The goal of Project Call 5.1 is to perform small group studies that will help determine the variability associated with key product attributes for therapeutic proteins while investing in state-of-the-art analytical instrumentation infrastructure that will be available across the NIIMBL community.
“This project call is a complement to our recent and future project calls and helps to build infrastructure for NIIMBL efforts in one of the important product characterization technologies for our community,” said Chris Roberts, associate institute director at NIIMBL, in the press release. “It was implemented in a similar way to recent rapid project calls from NIIMBL that are in parallel with our multi-stage project calls such as PC5.2 that is expected to be announced later this year.”
Detailed breakdowns of each study can be found at the
Source:
Advertisement
Related to this article
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement